Roche ’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Roche announced today that OCREVUS ® (ocrelizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), marking the second approval of OCREVUS for both indications following the FDA decision in th e US in March 2017.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news